Pharmacoeconomic Evaluation of Antidiabetic Agents-Metformin Plus Teneligliptin Versus Metformin Plus Glimepiride-A Prospective Study
Nimmy N John*, Arjun V J, Darath David, H. Doddayya.
N.E.T. Pharmacy College, Raichur- 584103, Karnataka,
India
ABSTRACT
Diabetes
mellitus is a metabolic-cum-vascular disorder of numerous etiologies described
by constant hyperglycemia with aggravations of sugar, fat and protein digestion
coming about deformities in insulin emission, insulin activity or both. This
issue is every now and again connected with long haul harm, which can prompt
disappointment of organs like eyes, kidney, nerves, heart and veins.. In India,
diabetes mellitus is influencing 33% of the grown-up populace. It is basically
connected with wellbeing trouble just as high financial weight at individual
and populace levels. A forthcoming observational investigation was completed
in-patients confessed to general medication division of NMCH&RC determined
to have diabetes mellitus endorsed with combination treatment of Metformin +
Glimepiride and combination treatment of Metformin + Teneligliptin from
September 2019 to February 2020. Information was gathered from case sheets of
patients and evaluated for their monetary weight dependent on the expense per
tablet for long term. Cost viability proportion for the patients with
controlled blood glucose level by utilizing a specific medication was
determined and likelihood to lessen the diabetes mellitus was assessed. Among
70 in-patients, 38 patients (54.29%) were males and 32 patients (45.71%) were
females. Patients are between the age gathering of 41-60 years were more
(48.57%). Majority of the patients were conceded with known history of diabetes
mellitus (81.43%). A large portion of the patients were endorsed with combination
treatment of Metformin + Glimepiride (81.42%) followed with Metformin +
Teneligliptin (18.57%). There was a critical positive connection (i.e., p
value= 0.5607) between perseverance examples of patients with drug treatment.
Likelihood of patients taking combination treatment of Metformin + Glimepiride
was 77.19% trailed by patients with combination treatment of Metformin +
Teneligliptin. Combination treatment of Metformin + Glimepiride are having more
Cost adequacy proportion. This investigation obviously indicated that combination
treatment of Metformin + Glimepiride is the most practical treatment among
other combination treatment to lessen monetary weight to the patient just as to
diminish the entanglements. Pharmacoeconomic assessments can help in creation
troublesome decisions judiciously and designate scant assets productively.
Keywords: Diabetes
mellitus, Treatment Pharmacoeconomics, Cost effectiveness, Hyperglycaemia